Home / Health / New Protein Offers Hope for Schizophrenia Treatment
New Protein Offers Hope for Schizophrenia Treatment
23 Mar
Summary
- Reduced Cacna2d1 protein levels linked to schizophrenia circuits.
- Synthetic protein SEAD1 corrected brain activity in mice.
- Discovery may lead to novel biomarker and therapeutic approaches.
A groundbreaking study has identified a novel biomarker for schizophrenia, offering a potential new avenue for treating cognitive deficits associated with the disorder. Researchers at Northwestern University analyzed cerebral spinal fluid from over 100 individuals and found reduced levels of the brain protein Cacna2d1 in schizophrenia patients. This deficiency was linked to overexcited brain circuits, contributing to cognitive symptoms like disorganized thinking.
The study introduced a synthetic version of the protein, named SEAD1. When administered to a mouse model of schizophrenia, a single injection of SEAD1 effectively corrected abnormal brain activity and behavioral issues. This discovery could lead to a new treatment strategy employing a biomarker-peptide therapeutic approach.
This research holds significant promise, as it could enable the identification of patient subgroups likely to respond to SEAD1-based treatments. Beyond schizophrenia, the ability to rewire connections in adult brains might also benefit conditions like depression, offering broader therapeutic potential.
